

To: UPHS Physicians and Staff

From: Adam Bagg, MD, Director of Hematology, Division of Hematopathology
Joshua Edwards, MBA, Technical Manager- Hematopathology

Date: April 1, 2021

Re: Hemoglobin Identification Testing for Hemoglobinopathies

The Hematopathology Laboratory at HUP has evaluated and validated a new platform (Sebia Capillarys 3 Octa and Sebia Hydrasys 2) for the evaluation of hemoglobinopathies. This platform provides fully automated evaluation by alkaline capillary electrophoresis of hemoglobin subtypes with a reflex to acid agarose gel electrophoresis for variant confirmation. The reference ranges have been updated as follows:

Hgb A	96.8 – 97.8%
Hgb A2	2.2 – 3.2%
Hgb F	0 – 2%

Please continue using the same order in Penn Chart, and follow the same process of sending the peripheral blood specimen to the Laboratory. All orders placed starting Monday, April 5, 2021 will automatically route to this new testing. For details about specimen collection, transport, and result interpretation, refer to the Laboratory Test Services Guide, available through the [Penn Medicine Intranet](#). Please note that specimen collection requirements have been updated to include a concurrent CBC at the time of collection, if one has not already been ordered, in order to facilitate interpretation of hemoglobin identification testing.

If you need any further clarification of this testing change, please contact Joshua Edwards, Manager of the Hematopathology Laboratory, for assistance at either joshua.edwards@penntest.com or 267-319-5622.

